The antiviral effect of interferon was studied in a number of experimental virus infections in the rat. Interferon was shown to protect rats infected with pseudorabies virus, herpes simplex virus or vesicular stomatitis virus. The antiviral activity was not inhibited by immune suppression induced by azothioprine, prednisolone or cyclosporin A treatment. Cyclophosphamide completely blocked the in vivo activity of interferon in rats.
INTRODUCTION
Interferons are proteins secreted by eukaryotic cells after virus infection or other stimuli. They have antiviral, anti-tumour and immuno-modulating activities in vitro and in vivo (Stewart, 1981) . Although the use of interferon as an antiviral agent for certain conditions in man has been established (WHO Scientific Group, 1982) , the potential of its clinical application is still unknown because of the limited availability of interferons.
Animal studies are an essential preliminary step to the application of interferon in man. Many of the studies of antiviral activity of interferons in experimental animals were performed in mice and studies of the effects of interferons in other species may also further increase our knowledge of the interferon system (Kern & Glasgow, 1981) .
We report here the development of models for studing the antiviral activity of homologous interferon in rats. There is only one report on the in vivo antiviral activity of rat interferon in newborn rats infected with Sindbis virus (Denys, 1963) . Since there are few data on experimental infection in rats we first had to find suitable experimental virus infections and then investigate the effects of interferon in these infections. We have also studied the influence of several immune suppressive drugs on the antiviral effect of interferon in vivo.
METHODS
Interferon production and assay. Rat interferon was produced as described previously, with some minor modifications (Schellekens et al., 1980) . Instead of Newcastle disease virus, Sendai virus (Flow Eaboratories) was used and only (NH~)zSO4 was used to precipitate the interferon. The interferon preparation had an activity of 104~ to 105.0 units/ml and a specific activity of about 105 units/mg protein. Interferon was assayed as previously described (Schellekens et al., 1980) in a c.p.e, inhibition assay. Activity is expressed in units standardized against a laboratory rat interferon reference.
Animals. Except when stated otherwise, 6-week-old SPF WAG/Rij rats from the colony of the REPGO Institutes (Rijswijk, The Netherlands) were used. Experiments were performed under quarantine conditions.
Viruses. Vesicular stomatitis virus (VSV) Indiana strain was originally obtained from the American Type Culture Collection and was passaged at low m.o.i, in L929 cells and Ratec cells for an unknown number of times. Herpes simplex virus type 1 (HSV-1) was originally isolated in human embryo lung (HEL) cells from a patient with a fever blister. The Virus was passaged three times in L929 cells. The batch used in these studies was passaged in Ratec cells. The pseudorabies virus was obtained from the Centraal Diergeneeskundig Instituut, Lelystad, The Netherlands as an original field isolate in PKI5 cells. The batches used in this study were the 3rd and 4th passages in Ratec cells. The vaccinia virus employed was the Dutch vaccination strain (Hekker et al., 1973) obtained from the Rijksinstituut voor Volksgezondheid, Bilthoven, The Netherlands. Except for the vaccinia virus, the viruses H. SCHELLEKENS AND OTHERS were assayed in Ratec cells using the c.p.e, test and the titres expressed in c.p.e. Ds0. The animals were infected with 10 times the dose which proved lethal for /> 80% of the animals (10 LD8o).
Statistics. Analysis of the results was by use of the Fisher exact probability test (Siegel, 1956) . A probability of < 5% is taken to mean a significant difference in the number of survivors in the groups compared.
Drugs. Cyclosporin A was a gift of Dr J. F. Borel (Sandoz, Basle, Switzerland). It was dissolved in neutral oil (Miglyol 812R; Dynamit Nobel) at a concn, of 100 mg/ml. Cyclophosphamide (EndoxanR; Astawerke AG, Bielefeld, F.R.G.) was dissolved in 0.9% saline at a concn, of 2 mg/ml. Prednisolone (Di-adreson-F aquosum; Organon, Oss, The Netherlands) containing 25 rag/ampoule was dissolved in phosphate-buffered saline to a concn, of 5 mg/ml. Azothioprine (Imuran R) was kindly provided by Wellcome Reagents, The Netherlands, and was dissolved in 0.9% saline to a concn, of 20 mg/ml RESULTS As a preliminary study, we investigated the effects of four viruses in the rat. The results are summarized in Table 1 . All viruses were lethal for newborns and rats of 4 to 6 weeks of age, except for vaccinia virus, which was lethal for newborns but not for 4-to 6-week-old rats. Of the viruses and routes of infection tested, only pseudorabies virus injected intraperitoneally and intranasal infection with VSV proved to be lethal for rats older than 6 weeks. Rats were found to be very sensitive to pseudorabies virus. A relatively low challenge dose of 103 c.p.e. Ds0 is lethal for more than 80% of all rat strains tested. The rats died within 2 to 3 days, probably because of massive hepatic necrosis. This sensitivity was independent of age, since rats of different ages ranging up to more than 1 year old proved equally sensitive.
The antiviral effect of rat interferon was then studied in different virus infections. The results of four experiments in which the antiviral effects of different doses of rat interferon were tested in pseudorabies virus-infected rats are given in Table 2 . Interferon was injected daily on three consecutive days, starting on the day before infection. Doses of 1000 to 1500 units daily exerted a significant antiviral effect. Doses of 20000 units of rat interferon administered daily for three consecutive days, starting on the day before infection, also protected a significant number of rats against intraperitoneal infection with VSV. When the rats were infected intranasally with the same virus, however, there was no effect (Table 3 ). The same treatment schedule which had no effect on intranasal VSV infection led to significant antiviral activity against intranasal HSV-1 infection (Table 4) .
A possible application of interferon in man is for the prevention of virus infections in immunosuppressed patients (Hirsch et al., 1981) . Since impairment of the host defence mechanisms by immunosuppression may interfere with the antiviral effect of interferon in vivo (Schellekens et al., 1979 , we tested the antiviral activity in immunosuppressed rats * Interferon was administered intraperitoneally at 20000 units daily at -24 h, 0 h and +24 h. At 0 h, the animals, 4-week-old rats, were infected intraperitoneally or intranasally with 10 LDso VSV. t P < 5~ in Fisher exact test when compared with untreated controls. 
DISCUSSION
This study shows that rat interferon has in vivo antiviral activity against pseudorabies virus, VSV and HSV-1 infections. Of these, pseudorabies virus infection proved to be an excellent model for testing the antiviral activity in vivo. Independent of age, the virus was lethal in rats within 2 to 3 days and the infection was very sensitive to interferon; 1000 units daily for 3 days at * The rats were infected intraperitoneally at 0 h with 10 LD80. 20000 units interferon were injected intraperitoneally daily on days -24 h, 0 h and + 24 h. I" One mg cyclosporin A or 10 mg cyclophosphamide was administered intraperitoneally on days -24 h and 0 h. :~ P < 5~ in Fisher exact test when compared with untreated controls. § P > 5~ in Fisher exact test when compared with interferon-treated group. II P < 5~ in Fisher exact test when compared with cyclophosphamide + interferon-treated group. * The rats were infected intraperitoneaUy at 0 h with 10 LDs0 pseudorabies virus. 3000 units interferon were administered daily at -24 h, 0 h and + 24 h. One nag cyclosporin A, 4 mg azothioprine or 3 mg prednisolone were injected intraperitoneally at -24 h, 0 h and + 24 h. t P < 5~ in Fisher exact test when compared with untreated controls.
-24 h, 0 h and + 24 h after infection gave complete protection. The interferon treatment, however, must be started before infection. Treatment initiated on the day after infection had no effect (Schellekens & van der Meide, 1983) . There have been reports that interferon is active after infection when very high doses are applied (Gresser et al., 1975) ; perhaps, the dose we applied was too low.
Rat interferon is active against VSV infection in vivo only when the virus is administered intraperitoneally. There is no protection after intranasal infection when VSV is assumed to spread via the olfactory nerve to the brain (Sabin & Olitsky, 1938) . Apparently, either interferon or the host defence mechanisms activated cannot protect the olfactory nerve, or the nerve cells are not sensitive to the activity of interferon. This contrasts with the protective effect of interferon on intranasal VSV infection in mice in roughly comparable doses (De Clercq et al., 1970; De Clercq & De Somer, 1971) . However, HSV-1 administered intranasally to rats and thought to travel by the same route also proved to be sensitive to interferon treatment. Therefore, other factors such as virus strain, timing and dose of virus or interferon could also be important for the sensitive intranasal infection in different species.
Azothioprine, prednisolone and cyclosporin A did not interfere with the antiviral activity of interferon in rats. Prednisolone and cyclosporin A were administered in doses which are comparable to those used in man and which have immune suppressive effects in rats (Shehadeh et al., 1970; Niessen et al., 1982) . Azothioprine has little immune suppressive effect in rats, but the dosage we used was based on that applied in man (Shehadeh et al., 1970) . We have reported previously that neither azothioprine/prednisolone nor anti-lymphocyte serum interfered with the activity of human interferons in vaccinia virus-infected rhesus monkeys (Schellekens et al., 1982) . Patients subjected to immune suppressive regimens are likely candidates for interferon therapy to prevent virus infections (Hirsch et al., 1981) . From our results, it seems likely that this immune suppression will not influence the activity of interferon.
Cyclophosphamide in a dose that has been reported to be immune-suppressive in rats (van Bekkum et al., 1969) did abolish the antiviral effect of interferon. Host defence mechanisms seem to contribute to the antiviral effect of interferon in vivo. The blocking of the antiviral effect of interferon in vivo by cyclophosphamide, while other immune-suppressive agents have no effect, can provide a means of identifying the cellular part of the host immune systems that may contribute to the antiviral effect of interferon in vivo. An additional way of achieving this goal may be by the transfer of spleen cells from rats treated with interferon to untreated rats. Such transfer of protective activity against infection with VSV has been observed . We have attempted to extend these observations to the pseudorabies virus model, but without success.
Rats have seldom been used for the study of virus infections or of interferon activity. The present study shows that this species is suitable for this type of research, and that pseudorabies virus infection in the rat provides a practical model system.
